Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies

One of the obstacles limiting progress in the development of effective cancer therapies is the shortage of preclinical models that capture the dynamic nature of tumor microenvironments. Interstitial flow strongly impacts tumor response to chemotherapy; however, conventional in vitro cancer models la...

Full description

Saved in:
Bibliographic Details
Published in:Advanced healthcare materials 2022-01, Vol.11 (1), p.e2101085-n/a
Main Authors: Prince, Elisabeth, Kheiri, Sina, Wang, Yihe, Xu, Fei, Cruickshank, Jennifer, Topolskaia, Valentina, Tao, Huachen, Young, Edmond W. K., McGuigan, Alison. P., Cescon, David W., Kumacheva, Eugenia
Format: Article
Language:English
Subjects:
Anticancer properties
Antineoplastic drugs
Antitumor agents
Arrays
Biomimetics
Breast cancer
Breast Neoplasms - drug therapy
cancer
Cancer therapies
Cell Line, Tumor
Chemotherapy
Customization
Dosage
Drug development
Drug efficacy
Drug Evaluation, Preclinical
Drug screening
drug testing
Early Detection of Cancer
Female
Humans
Hydrogels
Microfluidics
personalized medicine
preclinical models
Screening
Spheroids
Spheroids, Cellular
Tumor Microenvironment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the obstacles limiting progress in the development of effective cancer therapies is the shortage of preclinical models that capture the dynamic nature of tumor microenvironments. Interstitial flow strongly impacts tumor response to chemotherapy; however, conventional in vitro cancer models largely disregard this key feature. Here, a proof of principle microfluidic platform for the generation of large arrays of breast tumor spheroids that are grown under close‐to‐physiological flow in a biomimetic hydrogel is reported. This cancer spheroids‐on‐a‐chip model is used for time‐ and labor‐efficient studies of the effects of drug dose and supply rate on the chemosensitivity of breast tumor spheroids. The capability to grow large arrays of tumor spheroids from patient‐derived cells of different breast cancer subtypes is shown, and the correlation between in vivo drug efficacy and on‐chip spheroid drug response is demonstrated. The proposed platform can serve as an in vitro preclinical model for the development of personalized cancer therapies and effective screening of new anticancer drugs. The authors present a microfluidic (MF) platform for the generation of massive arrays of breast tumor spheroids for personalized cancer therapy and drug screening. The platform facilitates drug screening under physiological flow. MF arrays of patient‐derived breast tumor organoids are also generated for the development of personalized cancer therapies.
ISSN:2192-2640
2192-2659
DOI:10.1002/adhm.202101085